Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

IntraDose NDA to receive fast track review by FDA

May 14, 1999

Glaxo reports kinase inhibitors especially useful for chemotherapy-induced alopecia

May 14, 1999

Microtubule disruption by T-138067 produces potent anticancer activity in MDR tumors

May 14, 1999

Exisulind leads to lower PSA levels according to interim phase II/III data

May 13, 1999

AstraZeneca launches Casodex 80 mg in Japan for treatment of prostate cancer

May 12, 1999

POH enters additional phase II trials

May 12, 1999

Trimelamol analogue available for licensing from CRCT

May 12, 1999

Isis initiates phase II clinical trials of ISIS-2503

May 11, 1999

Non-cysteine-containing FTase inhibitors from Abbott with good oral bioavailability

May 11, 1999

Telomerase inhibitors available for licensing from CRCT

May 11, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.